KIT and neoplasm: Thus, the authors of this consensus statement recommended the combined assessment of different factors, including clinical staging, history of tumor recurrence, histopathological grade (Patnaik and Kiupel gradations and mitotic count) and molecular data, highlighting the assessment of Ki-67 level, expression of KIT, and detection of mutations in KIT, mainly in intermediate- to high-risk cutaneous MCTs [148].